Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind, Placebo-controlled Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV-16 Infected Women With Normal Cytology, CIN1 or CIN2

NCT04490512 is registered in ClinicalTrials.gov with BlueSky Immunotherapies GmbH as lead sponsor.

NCT NCT04490512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04490512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind, Placebo-controlled Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV-16 Infected Women With Normal Cytology, CIN1 or CIN2
Lead sponsor
BlueSky Immunotherapies GmbH
Phase
Phase 1
Overall status
Completed
Start date
December 9, 2020
Completion date
June 6, 2023
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hpv infection